Response-guided peginterferon therapy in hepatitis B e antigen-positive chronic hepatitis B using serum hepatitis B surface antigen levels-Reference-Cited by-同舟云学术

Response-guided peginterferon therapy in hepatitis B e antigen-positive chronic hepatitis B using serum hepatitis B surface antigen levels

Published:2013-07-29 Issue:3 Volume:58 Page:872-880
ISSN:0270-9139
Container-title:Hepatology
language:en
Short-container-title:Hepatology

Author:

Sonneveld Milan J.¹,Hansen Bettina E.,Piratvisuth Teerha²,Jia Ji-Dong³,Zeuzem Stefan⁴,Gane Edward⁵,Liaw Yun-Fan⁶,Xie Qing⁷,Heathcote E. Jenny⁸,Chan Henry L.-Y.⁹,Janssen Harry L.A.

Affiliation:

1. Department of Gastroenterology and Hepatology; Erasmus MC University Medical Center; Rotterdam; The Netherlands

2. NKC Institute of Gastroenterology and Hepatology; Songklanagarind Hospital, Prince of Songkla University; Hat Yai; Thailand

3. Liver Research Center; Beijing Friendship Hospital, Capital Medical University; Beijing; China

4. Medical Clinic 1; Johann Wolfgang Goethe University Medical Center; Frankfurt; Germany

5. Liver Unit; Auckland City Hospital; Auckland; New Zealand

6. Liver Research Unit; Chang Gung Memorial Hospital, Chang Gung University College of Medicine; Taipei; Taiwan

7. Department of Infectious Diseases; Ruijin Hospital; Shanghai; China

8. Division of Gastroenterology; University Health Network; Toronto; Canada

9. Department of Medicine and Therapeutics and Institute of Digestive Disease; Chinese University of Hong Kong; Hong Kong SAR; China

Publisher

Wiley

Subject

Hepatology

Reference29 articles.

1. Hepatocellular carcinoma and hepatitis B virus;Chan;Semin Liver Dis,2006

2. A randomized, controlled trial of combination therapy for chronic hepatitis B: comparing pegylated interferon-alpha2b and lamivudine with lamivudine alone;Chan;Ann Intern Med,2005

3. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial;Janssen;Lancet,2005

4. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B;Lau;N Engl J Med,2005

5. Shorter durations and lower doses of peginterferon alfa-2a are associated with inferior hepatitis B e antigen seroconversion rates in hepatitis B virus genotypes B or C;Liaw;Hepatology,2011

Cited by 204 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Editorial: Trajectory of soluble programmed cell death protein‐1 and ligand‐1 in HBV‐infected individuals treated with pegylated interferon—implications for stopping rules and the HBV cure programme;Alimentary Pharmacology & Therapeutics;2024-07-17

2. Predictive models for functional cure in patients with CHB receiving PEG-IFN therapy based on HBsAg quantification through meta-analysis;Hepatology International;2024-06-24

3. Prediction model for hepatitis B e antigen seroconversion in chronic hepatitis B with peginterferon-alfa treated based on a response-guided therapy strategy;World Journal of Hepatology;2024-03-27

4. Addition of PEG‐interferon to long‐term nucleos(t)ide analogue therapy enhances HBsAg decline and clearance in HBeAg‐negative chronic hepatitis B;Journal of Viral Hepatitis;2024-01-19

5. Mechanism of interferon alpha therapy for chronic hepatitis B and potential approaches to improve its therapeutic efficacy;Antiviral Research;2024-01